An educational overview of the peptide classes studied for weight management and metabolic function. This page covers GLP-1 receptor agonists, dual and triple incretins, growth hormone fragments, amylin analogs, and mitochondrial-derived metabolic peptides — with research context, mechanism summaries, and links to tools.
Peptides studied in the context of weight management span several distinct mechanistic categories. Each class targets different physiological pathways, and their level of clinical evidence varies significantly.
| Category | Mechanism | Examples |
|---|---|---|
| GLP-1 agonists | Appetite suppression, insulin signaling | Semaglutide |
| Dual incretins | GLP-1 + GIP signaling | Tirzepatide |
| Triple incretins | GLP-1 + GIP + Glucagon | Retatrutide |
| GH fragments | Fat metabolism without growth effects | AOD-9604 |
| Metabolic peptides | Cellular energy pathways | MOTS-c, 5-Amino-1MQ |
| Amylin analogs | Satiety signaling | Cagrilintide |
The sections below explore each category in more detail, including the key compounds, their mechanisms of action, current regulatory status, and the strength of the available research evidence.
GLP-1 (glucagon-like peptide-1) agonists are the most extensively studied class of peptides for weight management. These compounds mimic the endogenous GLP-1 hormone, which is produced in the L-cells of the small intestine after eating. By binding to GLP-1 receptors in the brain, gut, and pancreas, they produce a coordinated set of metabolic effects.
Semaglutide is the most widely recognized GLP-1 agonist. It suppresses appetite by acting on hypothalamic neurons involved in hunger signaling, slows gastric emptying to prolong post-meal satiety, and enhances glucose-dependent insulin secretion. In the STEP clinical trial program, semaglutide at 2.4 mg weekly demonstrated mean body weight reductions of approximately 15–17% over 68 weeks compared to placebo.
The mechanism is primarily central — GLP-1 agonists cross the blood-brain barrier and act on areas such as the arcuate nucleus and the area postrema, reducing the subjective experience of hunger and food-seeking behavior. Peripheral effects on gastric motility and insulin dynamics contribute to overall metabolic improvements.
Semaglutide has received FDA approval under brand names Wegovy (for chronic weight management) and Ozempic (for type 2 diabetes). Its long half-life of approximately 7 days allows for once-weekly administration.
For a detailed guide on semaglutide, see our Semaglutide educational page.
While GLP-1 agonists target a single receptor, researchers have developed compounds that simultaneously activate multiple incretin and metabolic receptors. The rationale is that engaging additional pathways may amplify weight loss effects and address a broader range of metabolic dysfunctions.
Tirzepatide is a dual GLP-1/GIP receptor agonist. By activating the GIP (glucose-dependent insulinotropic polypeptide) receptor alongside GLP-1, tirzepatide engages additional insulin-stimulating and fat-metabolism pathways. In the SURMOUNT-1 trial, participants receiving the highest dose (15 mg) achieved mean weight reductions of approximately 22.5% over 72 weeks — exceeding the results observed with semaglutide alone. Tirzepatide is FDA-approved under brand names Mounjaro and Zepbound.
Retatrutide takes this approach further as a triple agonist targeting GLP-1, GIP, and glucagon receptors. The addition of glucagon receptor activation is hypothesized to increase energy expenditure and promote hepatic fat oxidation. Phase 2 clinical trial data showed mean weight reductions of approximately 24% at the highest dose over 48 weeks, with Phase 3 trials underway. Retatrutide remains investigational and has not yet received regulatory approval.
The progression from single to dual to triple agonism represents a core research trajectory in the incretin field — each additional receptor target introduces new mechanistic levers, but also increases the complexity of the pharmacological profile and the potential for varied physiological effects.
Learn more: Tirzepatide guide • Retatrutide guide
Beyond incretins, several other peptide classes have been studied for potential effects on fat metabolism and energy regulation. These compounds operate through distinct mechanisms unrelated to the GLP-1/GIP/glucagon receptor system.
AOD-9604 is a modified fragment (amino acids 177–191) of human growth hormone. It was designed to retain the fat-metabolic activity of growth hormone while eliminating its growth-promoting and diabetogenic effects. Preclinical studies suggested lipolytic activity (fat breakdown) without the IGF-1 elevation associated with full-length growth hormone. Clinical data in humans remains limited, and AOD-9604 has not received regulatory approval for weight management.
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide. It is encoded in mitochondrial DNA and appears to play a role in regulating cellular energy metabolism, particularly through AMPK activation and glucose utilization pathways. Preclinical research in animal models has shown effects on exercise mimicry, fat metabolism, and insulin sensitivity, but human clinical data is extremely limited.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule peptide-adjacent compound that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular energy metabolism. By reducing NNMT activity, 5-Amino-1MQ may increase NAD+ levels and promote metabolic activity in adipose tissue. Research is primarily preclinical, with in vitro and animal model data suggesting effects on fat cell metabolism.
These compounds represent an earlier stage of research compared to the incretin agonists. While their mechanisms are scientifically interesting, none have the level of clinical evidence that supports the GLP-1 and dual/triple agonist classes.
Related calculators: AOD-9604 calculator • MOTS-c calculator • 5-Amino-1MQ calculator
The following table summarizes the key peptides discussed on this page, their primary mechanisms, regulatory status, and the current level of clinical evidence supporting their use in weight-related research.
| Peptide | Mechanism | Status | Evidence Level |
|---|---|---|---|
| Semaglutide | GLP-1 agonist | FDA-approved | Strong (Phase 3, real-world) |
| Tirzepatide | GLP-1/GIP dual agonist | FDA-approved | Strong (Phase 3) |
| Retatrutide | GLP-1/GIP/Glucagon triple agonist | Investigational | Moderate (Phase 2–3) |
| AOD-9604 | GH fragment (aa 177–191) | Research | Preclinical + limited clinical |
| MOTS-c | Mitochondrial-derived peptide | Research | Preclinical |
Evidence levels reflect the breadth and quality of published research as of current literature. FDA-approved compounds have undergone large-scale randomized controlled trials, while research-stage peptides may have supporting preclinical data but lack robust human clinical evidence.
Measurement math tools for converting between mg, mL, and syringe units for weight-related peptides. These calculators perform concentration-based conversions only — they do not recommend doses.